The most important pharma story of the decade just changed its distribution model — and most investors are still modeling the old one.
By Ruslan Averin.
This is Ruslan Averin's note on the GLP-1 coverage retreat and the channel shift hiding inside it.
What's happening
Employers are walking back the benefit: about 10% plan to drop GLP-1 weight-loss coverage in 2027 per Business Group on Health (Mercer pegs large employers at 5%), and Cigna — a health insurer — cut the coverage for its own workforce in July. Today 67% of large employers cover the drugs; the direction of travel just reversed. The stated reason is arithmetic: "Even though we have seen the unit cost come down, the patient population keeps growing." Lower price times exploding volume still breaks a benefits budget.
The channel shift is the real story
The same week employers retreat, Novo Nordisk's Wegovy and Eli Lilly's oral GLP-1 sell direct-to-consumer at roughly $149 a month. That is not a coincidence — it is a substitution. The manufacturers built a cash-pay channel that undercuts the insurance middlemen, and employers are rationally exiting a benefit employees can now buy themselves for less than a phone plan.
The investor read
- For Lilly and Novo, this is margin-mix, not demand destruction. DTC at $149 trades rebate-laden insurance revenue for cleaner cash-pay economics and a vastly larger addressable population.
- The losers are the intermediaries. PBMs and benefits managers lose negotiating relevance in a category moving to direct purchase.
- Watch volume, not coverage headlines. If script counts keep climbing while employer coverage shrinks, the DTC thesis is confirmed and the moat deepens around the two manufacturers who can price at scale.
The bottom line
Coverage cuts read like bad news and are actually a stress test the GLP-1 franchise is passing: demand strong enough to survive losing its subsidy is the definition of pricing power. The duopoly's grip looks tighter after this, not looser.